<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id><journal-id journal-id-type="publisher-id">jbc</journal-id><journal-title>The Journal of Biological Chemistry</journal-title><issn pub-type="ppub">0021-9258</issn><issn pub-type="epub">1083-351X</issn><publisher><publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">5186</article-id><article-id pub-id-type="doi">10.1074/jbc.M805587200</article-id><article-id pub-id-type="pmid">19116207</article-id><article-categories><subj-group subj-group-type="heading"><subject>Mechanisms of Signal Transduction</subject></subj-group></article-categories><title-group><article-title>Functional Ryanodine Receptors in the Plasma Membrane of RINm5F Pancreatic &#x003b2;-Cells<xref ref-type="fn" rid="fn1">*</xref><xref ref-type="fn" rid="fn2">&#x00053;&#x020de;</xref><xref ref-type="fn" rid="fn3"/></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rosker</surname><given-names>Christian</given-names></name></contrib><contrib contrib-type="author"><name><surname>Meur</surname><given-names>Gargi</given-names></name><xref ref-type="fn" rid="fn4">1</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Emily J. A.</given-names></name><xref ref-type="fn" rid="fn4">1</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Colin W.</given-names></name><xref ref-type="corresp" rid="cor1">2</xref></contrib></contrib-group><aff id="N0x3b58ca0N0x4586a40">Department of Pharmacology, University of Cambridge, Cambridge CB2 1PD, United Kingdom</aff><author-notes><fn id="fn4"><label>1</label><p>Both authors contributed equally.</p></fn><fn id="cor1"><label>2</label><p> To whom correspondence should be addressed. Tel.: 44-1223-334058; E-mail: <email>cwt1000@cam.ac.uk</email>. </p></fn></author-notes><pub-date pub-type="ppub"><day>20</day><month>2</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>2</month><year>2009</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the copyright element. --><volume>284</volume><issue>8</issue><fpage>5186</fpage><lpage>5194</lpage><history><date date-type="received"><day>22</day><month>7</month><year>2008</year></date><date date-type="rev-recd"><day>11</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009, The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement><license license-type="open-access"><p><italic>Author's Choice</italic></p><p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution Non-Commercial License</ext-link> applies to Author Choice Articles</p></license></permissions><self-uri xlink:title="pdf" xlink:href="zbc00809005186.pdf"/><abstract><p>Ryanodine receptors (RyR) are Ca<sup>2+</sup> channels that mediate Ca<sup>2+</sup> release from intracellular stores in response to diverse intracellular signals. In RINm5F insulinoma cells, caffeine, and 4-chloro-<italic>m</italic>-cresol (4CmC), agonists of RyR, stimulated Ca<sup>2+</sup> entry that was independent of store-operated Ca<sup>2+</sup> entry, and blocked by prior incubation with a concentration of ryanodine that inactivates RyR. Patch-clamp recording identified small numbers of large-conductance (&#x003b3;<sub>K</sub> = 169 pS) cation channels that were activated by caffeine, 4CmC or low concentrations of ryanodine. Similar channels were detected in rat pancreatic &#x003b2;-cells. In RINm5F cells, the channels were blocked by cytosolic, but not extracellular, ruthenium red. Subcellular fractionation showed that type 3 IP<sub>3</sub> receptors (IP<sub>3</sub>R3) were expressed predominantly in endoplasmic reticulum, whereas RyR2 were present also in plasma membrane fractions. Using RNAi selectively to reduce expression of RyR1, RyR2, or IP<sub>3</sub>R3, we showed that RyR2 mediates both the Ca<sup>2+</sup> entry and the plasma membrane currents evoked by agonists of RyR. We conclude that small numbers of RyR2 are selectively expressed in the plasma membrane of RINm5F pancreatic &#x003b2;-cells, where they mediate Ca<sup>2+</sup> entry.</p></abstract></article-meta><notes><fn-group><fn id="fn1"><label>*</label><p>This work was supported by the <grant-sponsor>Wellcome Trust</grant-sponsor> and the <grant-sponsor>Biotechnology and Biological Sciences Research Council</grant-sponsor> (UK). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;<italic>advertisement</italic>&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn><fn id="fn2"><label>&#x00053;&#x020de;</label><p>The online version of this article (available at <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org">http://www.jbc.org</ext-link>) contains supplemental Tables S1&#x02013;S6.</p></fn><fn id="fn3"><label><inline-graphic xlink:href="flower.gif"/></label><p><italic>Author's Choice</italic>&#x02014;Final version full access.</p></fn></fn-group></notes></front><body><p>Ryanodine receptors (RyR)<xref ref-type="fn" rid="fn5">3</xref> and inositol 1,4,5-trisphosphate receptors (IP<sub>3</sub>R) (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref2">2</xref>) are the archetypal intracellular Ca<sup>2+</sup> channels. Both are widely expressed, although RyR are more restricted in their expression than IP<sub>3</sub>R (<xref ref-type="bibr" rid="ref3">3</xref>, <xref ref-type="bibr" rid="ref4">4</xref>). In common with many cells, pancreatic &#x003b2;-cells and insulin-secreting cell lines express both IP<sub>3</sub>R (predominantly IP<sub>3</sub>R3) (<xref ref-type="bibr" rid="ref5">5</xref>, <xref ref-type="bibr" rid="ref6">6</xref>) and RyR (predominantly RyR2) (<xref ref-type="bibr" rid="ref7">7</xref>). Both RyR and IP<sub>3</sub>R are expressed mostly within membranes of the endoplasmic (ER), where they mediate release of Ca<sup>2+</sup>. Functional RyR are also expressed in the secretory vesicles (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref9">9</xref>) or, and perhaps more likely, in the endosomes of &#x003b2;-cells (<xref ref-type="bibr" rid="ref10">10</xref>). Despite earlier suggestions (<xref ref-type="bibr" rid="ref11">11</xref>), IP<sub>3</sub>R are probably not present in the secretory vesicles of &#x003b2;-cells (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref13">13</xref>).</p><p>All three subtypes of IP<sub>3</sub>R are stimulated by IP<sub>3</sub> with Ca<sup>2+</sup> (<xref ref-type="bibr" rid="ref1">1</xref>), and the three subtypes of RyR are each directly regulated by Ca<sup>2+</sup>. However, RyR differ in whether their most important physiological stimulus is depolarization of the plasma membrane (RyR1), Ca<sup>2+</sup> (RyR2) or additional intracellular messengers like cyclic ADP-ribose. The latter stimulates both Ca<sup>2+</sup> release and insulin secretion in &#x003b2;-cells (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref14">14</xref>). The activities of both families of intracellular Ca<sup>2+</sup> channels are also modulated by many additional signals that act directly or via phosphorylation (<xref ref-type="bibr" rid="ref15">15</xref>, <xref ref-type="bibr" rid="ref16">16</xref>). Although they commonly mediate release of Ca<sup>2+</sup> from the ER, both IP<sub>3</sub>R and RyR select rather poorly between Ca<sup>2+</sup> and other cations (permeability ratio, <italic>P</italic><sub>Ca</sub>/<italic>P</italic><sub>K</sub> &#x0223c;7) (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref17">17</xref>). This may allow electrogenic Ca<sup>2+</sup> release from the ER to be rapidly compensated by uptake of K<sup>+</sup> (<xref ref-type="bibr" rid="ref18">18</xref>), and where RyR or IP<sub>3</sub>R are expressed in other membranes it may allow them to affect membrane potential.</p><p>Both Ca<sup>2+</sup> entry and release of Ca<sup>2+</sup> from intracellular stores contribute to the oscillatory increases in cytosolic Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<italic><sub>i</sub></italic>) that stimulate exocytosis of insulin-containing vesicles in pancreatic &#x003b2;-cells (<xref ref-type="bibr" rid="ref7">7</xref>). Glucose rapidly equilibrates across the plasma membrane (PM) of &#x003b2;-cells and its oxidative metabolism by mitochondria increases the cytosolic ATP/ADP ratio, causing K<sub>ATP</sub> channels to close (<xref ref-type="bibr" rid="ref19">19</xref>). This allows an unidentified leak current to depolarize the PM (<xref ref-type="bibr" rid="ref20">20</xref>) and activate voltage-gated Ca<sup>2+</sup> channels, predominantly L-type Ca<sup>2+</sup> channels (<xref ref-type="bibr" rid="ref21">21</xref>). The resulting Ca<sup>2+</sup> entry is amplified by Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release from intracellular stores (<xref ref-type="bibr" rid="ref7">7</xref>), triggering exocytotic release of insulin-containing dense-core vesicles (<xref ref-type="bibr" rid="ref22">22</xref>). The importance of this sequence is clear from the widespread use of sulfonylurea drugs, which close K<sub>ATP</sub> channels, in the treatment of type 2 diabetes. Ca<sup>2+</sup> uptake by mitochondria beneath the PM further stimulates ATP production, amplifying the initial response to glucose and perhaps thereby contributing to the sustained phase of insulin release (<xref ref-type="bibr" rid="ref23">23</xref>). However, neither the increase in [Ca<sup>2+</sup>]<italic><sub>i</sub></italic> nor the insulin release evoked by glucose or other nutrients is entirely dependent on Ca<sup>2+</sup> entry (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref24">24</xref>) or closure of K<sub>ATP</sub> channels (<xref ref-type="bibr" rid="ref25">25</xref>). This suggests that glucose metabolism may also more directly activate RyR (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref26">26</xref>) and/or IP<sub>3</sub>R (<xref ref-type="bibr" rid="ref27">27</xref>) to cause release of Ca<sup>2+</sup> from intracellular stores. A change in the ATP/ADP ratio is one means whereby nutrient metabolism may be linked to opening of intracellular Ca<sup>2+</sup> channels because both RyR (<xref ref-type="bibr" rid="ref28">28</xref>) and IP<sub>3</sub>R (<xref ref-type="bibr" rid="ref1">1</xref>) are stimulated by ATP.</p><p>The other major physiological regulators of insulin release are the incretins: glucagon-like peptide-1 and glucose-dependent insulinotropic hormone (<xref ref-type="bibr" rid="ref29">29</xref>). These hormones, released by cells in the small intestine, stimulate synthesis of cAMP in &#x003b2;-cells and thereby potentiate glucose-evoked insulin release (<xref ref-type="bibr" rid="ref30">30</xref>). These pathways are also targets of drugs used successfully to treat type 2 diabetes (<xref ref-type="bibr" rid="ref29">29</xref>). The responses of &#x003b2;-cells to cAMP involve both cAMP-dependent protein kinase and epacs (exchange factors activated by cAMP) (<xref ref-type="bibr" rid="ref31">31</xref>, <xref ref-type="bibr" rid="ref32">32</xref>). The effects of the latter are, at least partly, due to release of Ca<sup>2+</sup> from intracellular stores via RyR (<xref ref-type="bibr" rid="ref33">33</xref>&#x02013;<xref ref-type="bibr" rid="ref35">35</xref>) and perhaps also via IP<sub>3</sub>R (<xref ref-type="bibr" rid="ref36">36</xref>). The interplays between Ca<sup>2+</sup> and cAMP signaling generate oscillatory changes in the concentrations of both messengers (<xref ref-type="bibr" rid="ref37">37</xref>). RyR and IP<sub>3</sub>R are thus implicated in mediating responses to each of the major physiological regulators of insulin secretion: glucose and incretins.</p><p>Here we report that in addition to expression in intracellular stores, which probably include both the ER and secretory vesicles and/or endosomes, functional RyR2 are also expressed in small numbers in the PM of RINm5F insulinoma cells and rat pancreatic &#x003b2;-cells.</p><sec sec-type="methods"><title>EXPERIMENTAL PROCEDURES</title><p><italic>Cell Culture</italic>&#x02014;RINm5F cells were cultured at 37 &#x000b0;C in humidified air containing 5% CO<sub>2</sub> in RPMI 1640 medium containing <sc>l</sc>-glutamine (2 m<sc>m</sc>), fetal calf serum (10%), Hepes (1 m<sc>m</sc>), and 2-mercaptoethanol (50 &#x003bc;<sc>m</sc>). Cells were passaged every 3&#x02013;4 days when confluent.</p><p><italic>Isolation of Rat Pancreatic</italic> &#x003b2;<italic>-Cells</italic>&#x02014;Pancreatic &#x003b2;-cells were isolated from 3-week-old, male Wistar rats by Dr. Noel Smith (Department of Clinical Biochemistry) (<xref ref-type="bibr" rid="ref38">38</xref>). Briefly, the pancreas was perfused with Hank's balanced salt solution (HBSS, Sigma) containing collagenase P (1 mg/ml, Roche), excised and incubated at 37 &#x000b0;C for 15 min. The islets were then washed in cold HBSS (600 &#x000d7; <italic>g</italic>, 5 min) and purified using a Histopaque discontinuous gradient (Histopaque, 1.077 g/ml; Histopaque 1, 1.119 g/ml; Sigma). Dispersed cells were resuspended in RPMI medium and allowed to attach to poly-<sc>d</sc>-ornithine-coated Petri dishes for patch-clamp recordings from isolated cells.</p><p><italic>Subcellular Fractionation</italic>&#x02014;Confluent cells (1.2 &#x000d7; 10<sup>6</sup> cells) were washed twice with ice-cold phosphate-buffered saline (PBS: 136.9 m<sc>m</sc> NaCl, 2.7 m<sc>m</sc> KCl, 1.5 m<sc>m</sc> KH<sub>2</sub>PO<sub>4</sub>, 7.7 m<sc>m</sc> Na<sub>2</sub>HPO<sub>4</sub>, pH 7.4), scraped into 5 ml of the same medium, centrifuged (650 &#x000d7; <italic>g</italic>, 5 min) and resuspended in 850 &#x003bc;l of 0.3 <sc>m</sc> sucrose supplemented with Hepes (10 m<sc>m</sc>, pH 7.4), benzamidine (1 m<sc>m</sc>), NaN<sub>3</sub> (2 m<sc>m</sc>), protease inhibitors (1 Roche Applied Science complete protease inhibitor mini-tablet/10 ml) and dithiothreitol (5 m<sc>m</sc>). After homogenization (15 strokes in a Dounce homogenizer) and then passage through a 25-gauge needle (30 times), the homogenate was centrifuged (1000 &#x000d7; <italic>g</italic>, 10 min, to give pellet (P1) and supernatant (S1) fractions). The supernatant was then re-centrifuged (12,000 &#x000d7; <italic>g</italic>, 10 min, to give P2 and S2). Sucrose media were prepared in 100 m<sc>m</sc> KCl, 5 m<sc>m</sc> MgCl<sub>2</sub>, 100 m<sc>m</sc> imidazole, pH 6.8. Layers of 8.5% (1 ml), 40% (1.5 ml) and 60% (1.5 ml) sucrose were successively layered beneath 750 &#x003bc;l of the S2 supernatant fraction. The gradient was centrifuged (100,000 &#x000d7; <italic>g</italic>, 2 h, Beckman Coulter SW55T rotor), and fractions (0.25 ml, 1&#x02013;19) were collected from the top of the gradient.</p><p><italic>RNAi-mediated Knockdown of RyR1, RyR2, and IP<sub>3</sub>R3</italic>&#x02014;Cells (5 &#x000d7; 10<sup>5</sup> cells/well) grown in 6-well plates for 2 days were transfected using Lipofectamine RNAimax with a mixture of two RNAi for either RyR1, RyR2 (10 n<sc>m</sc> each, Invitrogen), or IP<sub>3</sub>R3 (10 n<sc>m</sc>, Qiagen). After 36&#x02013;48 h, cells were re-seeded (5 &#x000d7; 10<sup>5</sup> cells/well) and after a further 48 h transfected again with the same RNAi mixture. Cells were used 48&#x02013;60 h after the second transfection. The RNAi used are listed in supplemental Table S1.</p><p><italic>Immunoblotting and Protein Assays</italic>&#x02014;Cells (3 &#x000d7; 35-mm dishes) were washed twice in PBS and lysed (PBS with 1% Triton X-100). Protein concentrations were measured using the Quant-iT protein assay kit (Invitrogen). After SDS-PAGE (3&#x02013;8%, Invitrogen NuPAGE), proteins were transferred to a polyvinylidene difluoride membrane using an iBLOT apparatus (Invitrogen) and incubated with primary antibody. The antibodies used were: monoclonal IP<sub>3</sub>R3 (Transduction Laboratories, 1:1000), RyR2 (Calbiochem, 1:1000), rabbit RyR1 (<xref ref-type="bibr" rid="ref39">39</xref>) (1:1000), plasma membrane Ca<sup>2+</sup>-ATPase (Alexis, 1:1000) and rabbit polyclonal calnexin (Santa Cruz Biotechnology, 1:500). The blots were then incubated with horseradish peroxidase-conjugated donkey anti-rabbit (AbCam, 1:5000) or goat anti-mouse (Promega, 1:5000) secondary antiserum and visualized with SuperSignal West Pico chemiluminescent substrate (Pierce). Bands were quantified using GeneTools software (Syngene).</p><p><italic>Quantitative PCR</italic>&#x02014;Total RNA was isolated from cell lysates and reverse transcribed into cDNA (20 &#x003bc;l) using a fast lane cDNA direct kit (Qiagen). QPCR was performed on a Rotor-Gene 6000 (Corbett Research) in a final volume of 15 &#x003bc;l using Sensimix Plus SYBR master mix (Quantace), 0.5 &#x003bc;<sc>m</sc> actin primer or Quantitect primers for IP<sub>3</sub>R1&#x02013;3 and RyR1&#x02013;3, and 0.4 &#x003bc;l cDNA. Primers are listed in supplemental Table S2. QPCR conditions were: initial denaturation at 95 &#x000b0;C for 10 min, followed by 40 cycles at 95 &#x000b0;C for 10 s and 60 &#x000b0;C for 30 s. After the last cycle, a melting curve was performed to confirm the identity of the amplified product. Data were analyzed using quantification software supplied with Rotorgene 6000 (<xref ref-type="bibr" rid="ref40">40</xref>).</p><p><italic>Single Channel Recording</italic>&#x02014;Cells attached to uncoated plastic Petri dishes were rinsed with, and then incubated in, bath solution (BS) containing 140 m<sc>m</sc> cesium methanesulfonate, 10 m<sc>m</sc> Hepes, 500 &#x003bc;<sc>m</sc> BAPTA, 270 &#x003bc;<sc>m</sc> CaCl<sub>2</sub> (free [Ca<sup>2+</sup>] = 246 n<sc>m</sc>), pH 7.1. Where indicated, cesium methanesulfonate was iso-osomotically replaced by KCl, NaCl, Tris-HCl or <italic>N</italic>-methyl <sc>d</sc>-glucamine-HCl. Pipettes were pulled from borosilicate glass and had resistances of 10&#x02013;30 M&#x003a9; when filled with pipette solution (PS). Most recordings were performed with symmetrical solutions. Currents were recorded with an Axopatch 200B amplifier using pClamp 9.0, digitized at 10 kHz and filtered at 1 kHz. Capacitative currents were cancelled before recording. Single channel currents were recorded in the cell-attached or inside-out configuration of the patch-clamp technique. All recordings were performed at room temperature. Currents were analyzed using pClamp 9.0 software.</p><p><italic>Measurements of [Ca<sup>2</sup></italic><sup>+</sup><italic>]<sub>i</sub> and Mn<sup>2</sup></italic><sup>+</sup><italic>Entry</italic>&#x02014;Cells cultured on 22-mm round glass coverslips were incubated with Fura 2AM (2 &#x003bc;<sc>m</sc> prepared in anhydrous DMSO) in HBS supplemented with probenecid (2.5 m<sc>m</sc>) and Pluronic F127 (0.02%) for 45 min at 20 &#x000b0;C, followed by a further 45-min incubation to allow de-esterification of the indicator. HBS had the following composition: 135 m<sc>m</sc> NaCl, 5.9 m<sc>m</sc> KCl, 1.2 m<sc>m</sc> MgCl<sub>2</sub>, 11.6 m<sc>m</sc> Hepes, 11.5 m<sc>m</sc> glucose, and 1.5 m<sc>m</sc> CaCl<sub>2</sub> (replaced by 1 m<sc>m</sc> EGTA in Ca<sup>2+</sup>-free HBS), pH 7.3. Fluorescence ratios (excitation at 340 and 380 nm; emission at 510 nm) from single cells were collected at 20 &#x000b0;C at 5-s intervals. After correction for autofluorescence (by addition of 1 &#x003bc;<sc>m</sc> ionomycin with 10 m<sc>m</sc> MnCl<sub>2</sub>), fluorescence ratios were calibrated to [Ca<sup>2+</sup>]<sub>i</sub> using a look-up table created from standard Ca<sup>2+</sup> solutions (Molecular Probes).</p><p><fig position="float" id="fig1"><label>FIGURE 1.</label><caption><p><bold>Ca<sup>2+</sup> entry evoked by agonists of RyR.</bold><italic>A</italic>, Ca<sup>2+</sup> signals evoked by 4CmC (1 m<sc>m</sc>) in HBS with or without extracellular Ca<sup>2+</sup> and after pretreatment with ryanodine (400 &#x003bc;<sc>m</sc>, 30 min). Traces (here and in subsequent panels) show the responses from &#x0223c;50 individual cells taken from at least three independent experiments (means &#x000b1; S.E., but with many error bars smaller than the symbols). <italic>B</italic>, responses to caffeine (1 m<sc>m</sc>) in normal HBS. <italic>C</italic>, Ca<sup>2+</sup> signals evoked by 4CmC (1 m<sc>m</sc>) in Ca<sup>2+</sup>-free medium alone or after pretreatment with thapsigargin (<italic>TG</italic>, 1 &#x003bc;<sc>m</sc>). <italic>D</italic>, peak (after &#x0223c;30 s) and sustained (after 200 s) changes in [Ca<sup>2+</sup>]<italic><sub>i</sub></italic> evoked by 4CmC in the absence (<italic>open bars</italic>) and presence of extracellular Ca<sup>2+</sup>, and the latter after pretreatment (2 min) with nifedipine (<italic>Nif</italic>, 10 &#x003bc;<sc>m</sc>) or thapsigargin (1 &#x003bc;<sc>m</sc>). <italic>E</italic>, Mn<sup>2+</sup> entry (0.5 m<sc>m</sc>) was measured by quenching of Fura 2 fluorescence in control cells (<italic>Q1</italic>). Mn<sup>2+</sup> was then removed and the cells incubated with thapsigargin (1 &#x003bc;<sc>m</sc>) for 5 min (during the break between the traces) before again measuring Mn<sup>2+</sup> entry (<italic>Q2</italic>) in the presence of thapsigargin alone (<italic>black</italic>) or with 4CmC (1 m<sc>m</sc>, <italic>red</italic>). Typical traces are shown. Summary data show the slope of the fluorescence change during the second addition of Mn<sup>2+</sup> (Q2, with the stimulus) as a % (Q2/Q1) of the slope recorded during the first addition (Q1, without stimulus). Results are means &#x000b1; S.E., <italic>n</italic> = 30&#x02013;61. <italic>F</italic>, restoration of extracellular Ca<sup>2+</sup> (1.5 m<sc>m</sc>) to cells pretreated with thapsigargin (1 &#x003bc;<sc>m</sc>) in Ca<sup>2+</sup>-free HBS fails to evoke Ca<sup>2+</sup> entry.</p></caption><graphic xlink:href="zbc0130968490001"></graphic></fig></p><p>Quenching of fura 2 fluorescence by Mn<sup>2+</sup> entry was measured in similarly loaded cells bathed in Ca<sup>2+</sup>-free HBS supplemented with 0.5 m<sc>m</sc> MnCl<sub>2</sub> and with fluorescence recorded after excitation at 360 nm. For all experiments, a basal rate of quench (Q1) was measured before stimulation, and the rate was again measured after stimulation (Q2). The duration of the exposure to MnCl<sub>2</sub> (100 s) was chosen to ensure that rates of Fura 2 quenching were linear during both assay periods. The effects of stimuli on rates of Mn<sup>2+</sup> entry are reported as a Q2/Q1 ratio, with the ratio uniquely determined for each single cell (see <xref rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>).</p><p><italic>Materials</italic>&#x02014;Fura 2AM and all culture media, except serum (Sigma), were from Invitrogen. All other reagents, including ryanodine, caffeine, 4CmC, and ruthenium red, were from Sigma.</p></sec><sec><title>RESULTS AND DISCUSSION</title><p><italic>Ca<sup>2</sup></italic><sup>+</sup><italic>Entry Evoked by Agonists of RyR</italic>&#x02014;In single cell measurements of [Ca<sup>2+</sup>]<italic><sub>i</sub></italic> in RINmF5 insulinoma cells, most cells responded to caffeine (1 m<sc>m</sc>) or 4-chloro-<italic>m</italic>-cresol (4CmC, 1 m<sc>m</sc>) with a substantial increase in [Ca<sup>2+</sup>]<italic><sub>i</sub></italic> (<xref rid="fig1" ref-type="fig">Fig. 1, <italic>A</italic> and <italic>B</italic></xref>). A lower concentration of 4CmC (0.5 m<sc>m</sc>), sufficient to activate RyR1 and RyR2, but not RyR3 (<xref ref-type="bibr" rid="ref41">41</xref>), evoked a similar sustained Ca<sup>2+</sup> signal (&#x00394;[Ca<sup>2+</sup>]<italic><sub>i</sub></italic> = 275 &#x000b1; 18 and 176 &#x000b1; 11 n<sc>m</sc>, for 1 m<sc>m</sc> and 0.5 m<sc>m</sc> 4CmC, respectively). Treatment with a high, inactivating concentration of ryanodine (400 &#x003bc;<sc>m</sc>) evoked no Ca<sup>2+</sup> signal itself, but abolished the subsequent response to 4CmC (<xref rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>). Although each stimulus was effective in the absence of extracellular Ca<sup>2+</sup>, both the peak amplitude and sustained responses were substantially attenuated in Ca<sup>2+</sup>-free medium (<xref rid="fig1" ref-type="fig">Fig. 1, <italic>A</italic>&#x02013;<italic>D</italic></xref>).</p><p>Pretreatment of cells in Ca<sup>2+</sup>-free medium with thapsigargin (1 &#x003bc;<sc>m</sc>, 2 min) to empty the intracellular Ca<sup>2+</sup> stores that express the SR/ER Ca<sup>2+</sup>-ATPase (SERCA) massively reduced the 4CmC-evoked increase in [Ca<sup>2+</sup>]<italic><sub>i</sub></italic>, but without abolishing it (<xref rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>). The small residual Ca<sup>2+</sup> release is probably mediated by RyR in either secretory vesicles (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref9">9</xref>) or endosomes (<xref ref-type="bibr" rid="ref10">10</xref>), both of which can accumulate Ca<sup>2+</sup> by mechanisms that do not require SERCA (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref9">9</xref>). Quenching of fura 2 fluorescence evoked by unidirectional Mn<sup>2+</sup> entry across the PM was also stimulated by 4CmC (<xref rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>). These results establish that in RINm5F cells, agonists of RyR stimulate both release of intracellular Ca<sup>2+</sup> stores (from both ER and secretory vesicles or endosomes) and Ca<sup>2+</sup> entry. Others have also reported that agonists of RyR evoke Ca<sup>2+</sup> release and Ca<sup>2+</sup> entry in both &#x003b2;-cells and insulinoma cells (<xref ref-type="bibr" rid="ref20">20</xref>, <xref ref-type="bibr" rid="ref42">42</xref>).</p><p>In most cells, emptying of intracellular Ca<sup>2+</sup> stores evokes store-operated Ca<sup>2+</sup> entry (SOCE) across the PM, although SOCE is perhaps less widely expressed in electrically excitable cells (<xref ref-type="bibr" rid="ref43">43</xref>). Thapsigargin (1 &#x003bc;<sc>m</sc>) did not cause a substantial increase in [Ca<sup>2+</sup>]<italic><sub>i</sub></italic>, but it clearly emptied intracellular stores because it almost abolished the Ca<sup>2+</sup> release evoked by 4CmC (<xref rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>). However, thapsigargin caused no detectable Ca<sup>2+</sup> entry. The small responses to thapsigargin were similar in the presence and absence of extracellular Ca<sup>2+</sup> (not shown), and restoration of extracellular Ca<sup>2+</sup> to thapsigargin-treated cells failed to evoke a Ca<sup>2+</sup> signal (<xref rid="fig1" ref-type="fig">Fig. 1<italic>F</italic></xref>). Under similar conditions, the same stocks of thapsigargin stimulated both Ca<sup>2+</sup> release and SOCE in HEK cells (not shown). Furthermore, prior-treatment of RINm5F cells with thapsigargin neither evoked unidirectional Mn<sup>2+</sup> entry nor affected the Mn<sup>2+</sup> entry evoked by 4CmC (<xref rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>). We conclude that depletion of intracellular Ca<sup>2+</sup> stores fails to evoke significant SOCE in RINm5F cells. The lack of detectable SOCE is consistent with reports from insulinoma (<xref ref-type="bibr" rid="ref44">44</xref>) and &#x003b2;-cells (<xref ref-type="bibr" rid="ref20">20</xref>, <xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref45">45</xref>&#x02013;<xref ref-type="bibr" rid="ref47">47</xref>) where SOCE was either very small or undetectable.</p><p>Although agonists of RyR evoke Ca<sup>2+</sup> release (<xref rid="fig1" ref-type="fig">Fig. 1, <italic>B</italic> and <italic>C</italic></xref>) and SOCE is apparently absent from RINm5F cells (<xref rid="fig1" ref-type="fig">Fig. 1, <italic>E</italic> and <italic>F</italic></xref>), both the initial and sustained responses to caffeine (not shown) or 4CmC (<xref rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>) were substantially reduced in the absence of extracellular Ca<sup>2+</sup>. Blocking voltage-gated L-type Ca<sup>2+</sup> channels with nifedipine (10 &#x003bc;<sc>m</sc>) had no significant effect on either the peak or sustained responses to 4CmC, and nor had thapsigargin any effect on the sustained Ca<sup>2+</sup> signals evoked by 4CmC (<xref rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>).</p><p>Depolarization with 25 m<sc>m</sc> KCl (by replacement of NaCl) caused an increase in [Ca<sup>2+</sup>]<italic><sub>i</sub></italic> (by 291 &#x000b1; 12 n<sc>m</sc>, <italic>n</italic> = 48) that was substantially blocked (&#x0223c;60%) by 10 &#x003bc;<sc>m</sc> nifedipine (not shown). Under these depolarizing conditions and with nifedipine (10 &#x003bc;<sc>m</sc>) present, 4CmC (1 m<sc>m</sc>) evoked a further increase in [Ca<sup>2+</sup>]<italic><sub>i</sub></italic> of 169 &#x000b1; 21 n<sc>m</sc> (<italic>n</italic> = 46). The latter suggests that although 4CmC may lead to some activation of L-type Ca<sup>2+</sup> channels (note the small, but statistically insignificant, inhibition of the peak 4CmC-evoked Ca<sup>2+</sup> signal by nifedepine in <xref rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>), these channels can mediate no more than a very small component of the 4CmC-evoked Ca<sup>2+</sup> signal.</p><p>The results so far establish that agonists of RyR evoke Ca<sup>2+</sup> (or Mn<sup>2+</sup>) entry that is independent of SOCE or voltage-gated Ca<sup>2+</sup> channels. Another study also showed that a RyR-selective agonist stimulates Ca<sup>2+</sup> entry via a SOCE-independent pathway in &#x003b2;-cells, although it speculated that it resulted from RyR-mediated release of Ca<sup>2+</sup> from a non-ER store causing activation of Ca<sup>2+</sup>-permeable TRP (transient receptor potential) channels in the PM (<xref ref-type="bibr" rid="ref20">20</xref>). Our subsequent experiments show that the Ca<sup>2+</sup> entry is mediated directly by RyR in the PM.</p><p><italic>Differential Distributions of RyR and IP<sub>3</sub>R</italic>&#x02014;The quantitative PCR (QPCR) analysis shown in supplemental Table S3 and the immunoblots shown in <xref rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>, establish that RyR2 and IP<sub>3</sub>R3 are the major intracellular Ca<sup>2+</sup> channels in RINm5F cells. These results are consistent with previous reports demonstrating that IP<sub>3</sub>R3 (<xref ref-type="bibr" rid="ref5">5</xref>, <xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref48">48</xref>) and RyR2 (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref9">9</xref>, <xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref33">33</xref>, <xref ref-type="bibr" rid="ref49">49</xref>) are the major subtypes of intracellular Ca<sup>2+</sup> channels in pancreatic &#x003b2;-cells (<xref ref-type="bibr" rid="ref5">5</xref>, <xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref33">33</xref>, <xref ref-type="bibr" rid="ref48">48</xref>, <xref ref-type="bibr" rid="ref49">49</xref>) and RINm5F cells (<xref ref-type="bibr" rid="ref5">5</xref>, <xref ref-type="bibr" rid="ref6">6</xref>, <xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref48">48</xref>). Our results are also consistent with evidence showing low-level expression of RyR1 (<xref ref-type="bibr" rid="ref9">9</xref>, <xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref33">33</xref>) and with the lack of evidence that &#x003b2;-cells or insulinoma cells express RyR3 (<xref ref-type="bibr" rid="ref9">9</xref>).</p><p><fig position="float" id="fig2"><label>FIGURE 2.</label><caption><p><bold>Expression of RyR2 in RINm5F cells.</bold><italic>A</italic>, Western blots (60 &#x003bc;g protein/lane) from RINm5F cells stained with the indicated antibodies (typical of at least 3 blots). <italic>B,</italic> homogenate of RINm5F cells (see &#x0201c;Experimental Procedures&#x0201d;) was subjected to two centrifugation steps (as shown) and from each supernatant (<italic>S</italic>) and pellet (<italic>P</italic>), material equivalent to the same number of cells was analyzed by Western blotting. The distribution of each protein within the supernatant fraction is shown <italic>beneath</italic> each gel (mean &#x000b1; S.E., <italic>n</italic> = 3). The low level of expression of RyR1 (supplemental Table S3) prevented reliable quantification of its distribution after the first centrifugation step. The S2 supernatant was further analyzed on a discontinuous sucrose gradient, and fractions (0.25 ml, 1&#x02013;19) were analyzed by Western blotting. A typical blot is shown. <italic>C,</italic> The distribution of proteins between fractions (means &#x000b1; S.E., <italic>n</italic> = 3&#x02013;6) is shown as a percentage of that detected in fractions 6&#x02013;15 (none of the proteins were detected in the other fractions).</p></caption><graphic xlink:href="zbc0130968490002"></graphic></fig></p><p>IP<sub>3</sub>R3 and RyR2 were similarly distributed between the supernatant and pellet fractions after crude fractionation (<xref rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>). Although these simple analyses failed to separate PM and ER membranes, the results are consistent with the substantial presence of IP<sub>3</sub>R3 and RyR2 within intracellular Ca<sup>2+</sup> stores. However, sucrose-gradient centrifugation of a fraction (<italic>S2</italic> in <xref rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>) that included 20% of all IP<sub>3</sub>R3 and RyR2, clearly separated PM from ER, and IP<sub>3</sub>R3 from RyR2. IP<sub>3</sub>R3 appeared in the same fractions as calnexin, an integral ER protein, whereas RyR2 was concentrated in the same fractions as the plasma membrane Ca<sup>2+</sup>-ATPase (PMCA, <xref rid="fig2" ref-type="fig">Fig. 2, <italic>B</italic> and <italic>C</italic></xref>). These results do not prove that RyR2 are expressed in the PM, but they strongly suggest that at least some RyR2 are expressed in a different membrane compartment to IP<sub>3</sub>R3.</p><p><fig position="float" id="fig3"><label>FIGURE 3.</label><caption><p><bold>Caffeine and 4CmC activate the same large-conductance channels in the plasma membrane of RINm5F cells and pancreatic &#x003b2;-cells.</bold><italic>A</italic> and <italic>B,</italic> cell-attached (<italic>A</italic>) and excised patch (<italic>B</italic>) recordings from RINm5F cells with cesium methanesulfonate in both BS and PS at a holding potential of -100 mV. Caffeine (1 m<sc>m</sc>) or 4CmC (1 m<sc>m</sc>) were included in BS as indicated. In the <italic>bottom trace</italic> of each panel, cells were preincubated with ryanodine (400 &#x003bc;<sc>m</sc>, 30 min) before stimulating with caffeine. Traces are representative of &#x02265; 5(<italic>n</italic> = 2 for ryanodine) independent experiments (see &#x0201c;Results and Discussion&#x0201d;). <italic>Arrows</italic> denote closed state. For each recording, the <italic>boxed area</italic> is shown on an expanded timescale on the <italic>right. C</italic>, current-voltage relationship for channels activated by caffeine and 4CmC. Results are means &#x000b1; S.E. <italic>n</italic> = 6&#x02013;9 (most error bars are smaller than the symbols). <italic>D</italic>, typical excised patch recording from a rat pancreatic &#x003b2;-cell with cesium methanesulfonate in both BS and PS, at a holding potential of -40 mV, and with 4CmC (1 m<sc>m</sc>) included in BS as indicated. The <italic>boxed area</italic> is shown on an expanded timescale on the right. <italic>E</italic>, corresponding current-voltage relationship for &#x003b2;-cells (means &#x000b1; S.E., <italic>n</italic> = 5).</p></caption><graphic xlink:href="zbc0130968490003"></graphic></fig></p><p><italic>Plasma Membrane Channels Activated by Agonists of RyR</italic>&#x02014;In cell-attached patch-clamp recordings from RINm5F cells with cesium methansulphonate in both the bathing solution (BS) and pipette solution (PS), concentrations of 4CmC (1 m<sc>m</sc>) or caffeine (1 m<sc>m</sc>) typical of those used to activate RyR (<xref ref-type="bibr" rid="ref41">41</xref>) stimulated channel activity (<xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>). Pre-incubation (30 min) with a high concentration (400 &#x003bc;<sc>m</sc>) of ryanodine, sufficient to inhibit all RyR subtypes (<xref ref-type="bibr" rid="ref50">50</xref>), abolished responses to both stimuli (<xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>). Similar results were obtained with excised patches (<xref rid="fig3" ref-type="fig">Fig. 3<italic>B</italic></xref>). In both sets of recordings, G&#x003a9; seals were obtained in about 50% of attempts. The frequency with which channels were detected varied between 20 and 80% in different cell preparations. It is difficult to estimate reliably the average number of channels in a patch: too many large-conductance channels may prevent formation of a G&#x003a9; seal, and patches with undetected channels will include those that failed to respond for a variety of experimental reasons. However, most active patches included one or two active channels, and very few had 3&#x02013;4 channels: the average number of channels per excised patch was 1.8 &#x000b1; 0.2. An analysis that assumes a random distribution of channels between patches likewise suggests the presence of &#x0223c;2 channels/patch (supplemental Table S4). Assuming that our patch-clamp recordings are from &#x0223c;20% of the total PM, these results suggest the presence of fewer than &#x0223c;10 of these channels in the PM of each RINm5F cell. It proved impossible to achieve reliable whole cell recordings.</p><p>In symmetrical cesium methane sulfonate, the single channel slope conductance (&#x003b3;) measured in cell-attached patches was the same whether they were stimulated with caffeine (&#x003b3; = 147.7 &#x000b1; 4.5 pS, <italic>n</italic> = 6) or 4CmC (&#x003b3; = 148.3 &#x000b1; 4.2 pS, <italic>n</italic> = 9) (<xref rid="fig3" ref-type="fig">Fig. 3<italic>C</italic></xref>). We conclude that caffeine and 4CmC stimulate the same ryanodine-sensitive large-conductance cation channels in the PM of RINm5F cells.</p><p>Under similar recording conditions (symmetrical cesium methanesulphonate), 4CmC (1 m<sc>m</sc>) also activated channels in the PM of freshly isolated rat pancreatic &#x003b2;-cells (<xref rid="fig3" ref-type="fig">Fig. 3<italic>D</italic></xref>). The slope conductance of the major conductance of these channels (&#x003b3; = 151.5 &#x000b1; 6.3 pS, <italic>n</italic> = 5, <xref rid="fig3" ref-type="fig">Fig. 3<italic>E</italic></xref>) was similar to that in RIN cells.</p><p><fig position="float" id="fig4"><label>FIGURE 4.</label><caption><p><bold>Properties of ryanodine-activated channels in the plasma membrane.</bold><italic>A,</italic> ryanodine (4 n<sc>m</sc>) stimulates channel activity in excised patches, which is unaffected by clotrimazole (50 &#x003bc;<sc>m</sc>). Results show recordings in symmetrical cesium methane sulfonate at holding potentials of +80 mV (<italic>upper trace</italic> of each pair) and -80 mV (<italic>lower</italic>), each typical of &#x02265;4 recordings. <italic>Arrows</italic> denote closed state. <italic>B</italic>, current-voltage relationship for the major conductance of the ryanodine-stimulated channels (means &#x000b1; S.E., <italic>n</italic> &#x02265; 5). <italic>C</italic>, current amplitude histogram for ryanodine-evoked currents taken from a trace similar to that shown in <italic>A</italic> at -80 mV. <italic>Arrow</italic> denotes the current level equivalent to the major single channel conductance (&#x003b3; = 148 pS). <italic>D, E, P</italic><sub>o</sub> and mean open time (&#x003c4;<sub>o</sub>) for channels activated by ryanodine, 4CmC, and caffeine (means &#x000b1; S.E., <italic>n</italic> &#x02265; 5).</p></caption><graphic xlink:href="zbc0130968490004"></graphic></fig></p><p><italic>Properties of Ryanodine-activated Channels in the Plasma Membrane</italic>&#x02014;In excised inside-out patches, a low concentration of ryanodine (4 n<sc>m</sc>) activated channels that were unaffected by nifedipine (10 &#x003bc;<sc>m</sc>, not shown) or clotrimazole (<xref rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>); the latter at a concentration (50 &#x003bc;<sc>m</sc>) sufficient to inhibit K<sub>ATP</sub> and Ca<sup>2+</sup>-activated K<sup>+</sup> channels (<xref ref-type="bibr" rid="ref51">51</xref>, <xref ref-type="bibr" rid="ref52">52</xref>). The major conductance of the ryanodine-activated channels (&#x003b3;<sub>Cs</sub> = 147.8 &#x000b1; 3.7 pS, <italic>n</italic> = 7) was the same as that of the channels activated by caffeine and 4CmC (<xref rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>). The current-amplitude histograms consistently suggested the presence of minor sub-conductance states with amplitudes of &#x0223c;30&#x02013;50% that of the main conductance (<xref rid="fig4" ref-type="fig">Fig. 4<italic>C</italic></xref>). Such subconductance states are common features of RyR activated by ryanodine (<xref ref-type="bibr" rid="ref53">53</xref>). From patches with a single channel, the maximal open probability (<italic>P</italic><sub>o</sub> = 0.2&#x02013;0.3) was similar for caffeine (1 m<sc>m</sc>), 4CmC (1 m<sc>m</sc>) and ryanodine (4 n<sc>m</sc>) (<xref rid="fig4" ref-type="fig">Fig. 4<italic>D</italic></xref>), although the mean channel open time (&#x003c4;<sub>o</sub>) was significantly longer for ryanodine (<xref rid="fig4" ref-type="fig">Fig. 4<italic>E</italic></xref>). The latter is consistent with the established ability of low concentrations of ryanodine to cause long-lasting openings of RyR (<xref ref-type="bibr" rid="ref50">50</xref>).</p><p><fig position="float" id="fig5"><label>FIGURE 5.</label><caption><p><bold>Properties of 4CmC-activated channels in the plasma membrane.</bold><italic>A</italic>, cell-attached recordings were stimulated with 4CmC (1 m<sc>m</sc>) before excision into BS alone (<italic>lower</italic>) or supplemented with ruthenium red (10 &#x003bc;<sc>m</sc>, <italic>upper</italic>). Recordings were in symmetrical K<sup>+</sup> at +100 mV. <italic>Arrows</italic> denote closed state. <italic>B</italic>, typical recordings from excised patches held at -50 mV and stimulated with 4CmC (1 m<sc>m</sc>) in symmetrical media containing the indicated cations. <italic>C</italic>, current-voltage relationships from <italic>B</italic> (means &#x000b1; S.E., <italic>n</italic> &#x02265; 6, most error bars are smaller than the symbols).</p></caption><graphic xlink:href="zbc0130968490005"></graphic></fig></p><p>Ruthenium red is an antagonist of RyR, but it is membrane-impermeant. By first activating channels with 4CmC in the cell-attached configuration and then excising the patch into BS containing ruthenium red (100 &#x003bc;<sc>m</sc>), we demonstrated that cytosolic ruthenium red rapidly inhibits channel activity. <italic>P</italic><sub>o</sub> in the cell-attached configuration was 0.25 &#x000b1; 0.02 (<italic>n</italic> = 20), and remained at 0.24 &#x000b1; 0.04 after excision into normal BS, but fell within a few seconds to 0.005 &#x000b1; 0.01 after excision into BS containing ruthenium red (<xref rid="fig5" ref-type="fig">Fig. 5<italic>A</italic></xref>). These results provide substantial further evidence that the 4CmC-activated cation channels in the PM have the properties expected of RyR.</p><p><fig position="float" id="fig6"><label>FIGURE 6.</label><caption><p><bold>Activation of plasma membrane cation channels and cytosolic Ca<sup>2+</sup> signals requires RyR2.</bold><italic>A</italic>, Western blots showing expression of RyR2, IP<sub>3</sub>R3, and calnexin in RINm5F cells after transfection with RNAi for RyR1, RyR2, or IP<sub>3</sub>R3, or after mock transfection (control). The antibody to RyR1 cannot reliably detect changes in expression of endogenous RyR1, which is expressed at &#x0223c;10% that of RyR2 (supplemental Table S6). <italic>B</italic>, summary results show expression of RyR2 and IP<sub>3</sub>R3 derived from Western blots from four independent RNAi transfections (means &#x000b1; S.E.). <italic>C</italic>, typical recordings (at -50 mV) from patches excised from cells after transfection with RNAi for RyR2 or mock transfection. <italic>Arrows</italic> denote the closed state. <italic>D</italic>, percentage of cells in which 4CmC (1 m<sc>m</sc>) activated channels after successful formation of a G&#x003a9; seal in cells treated with RNAi for RyR1 (<italic>n</italic> = 21), RyR2 (<italic>n</italic> = 32) or after mock transfection (control, <italic>n</italic> = 38). <italic>E</italic>, Mn<sup>2+</sup> entry evoked by 1 m<sc>m</sc> 4CmC (with Q2/Q1 measured as in <xref rid="fig1" ref-type="fig">Fig. 1<italic>E</italic></xref>) for cells treated with RNAi for RyR2 or IP<sub>3</sub>R3, or after mock transfection (control). Results are means &#x000b1; S.E. for 35&#x02013;40 cells from two independent transfections. <italic>F</italic>, Ca<sup>2+</sup> signals evoked by 4CmC (1 m<sc>m</sc>) in cells transfected with RNAi for RyR2 or after mock transfection (control). Results are means &#x000b1; S.E., <italic>n</italic> = 47 and 32 cells, respectively. <italic>G</italic>, peak Ca<sup>2+</sup> signals evoked by 4CmC (1 m<sc>m</sc>) in cells treated with RNAi for RyR1, RyR2, or IP<sub>3</sub>R3, or after mock transfection (control). Means &#x000b1; S.E., <italic>n</italic> = 30&#x02013;76 cells.</p></caption><graphic xlink:href="zbc0130968490006"></graphic></fig></p><p>In excised patches stimulated with 4CmC (1 m<sc>m</sc>) under symmetrical ionic conditions, the channels were permeable not only to Cs<sup>+</sup> (&#x003b3;<sub>Cs</sub> = 148.3 &#x000b1; 4.2 pS, <italic>n</italic> = 9), but also to K<sup>+</sup> (&#x003b3;<sub>K</sub> = 169.0 &#x000b1; 4.8 pS, <italic>n</italic> = 5) and Na<sup>+</sup> (&#x003b3;<sub>Na</sub> = 130.2 &#x000b1; 2.1 pS, <italic>n</italic> = 4) (<xref rid="fig5" ref-type="fig">Fig. 5, <italic>B</italic> and <italic>C</italic></xref>). A similar number of channels and with similar <italic>P</italic><sub>o</sub> was detected under each of these conditions (not shown). The channels were impermeable to <italic>N</italic>-methyl-<sc>d</sc>-glucamine (NMDG) chloride (<xref rid="fig5" ref-type="fig">Fig. 5<italic>B</italic></xref>). Our attempts to measure Ba<sup>2+</sup> and Ca<sup>2+</sup> conductances were frustrated by resealing of membrane around the patch-pipette. We were, therefore, unable to determine the relative permeability of the PM channels for monovalent and bivalent cations. Comparison of &#x003b3; for the PM channels with analyses of RyR2 reconstituted into lipid bilayers (<xref ref-type="bibr" rid="ref54">54</xref>, <xref ref-type="bibr" rid="ref55">55</xref>) shows that after correction for the different ionic conditions, &#x003b3; of the PM channels is consistently 3&#x02013;4-fold lower than for RyR2 in bilayers (supplemental Table S5). Our previous analysis of IP<sub>3</sub>R expressed in the PM or nuclear envelope also suggested that exactly the same channel can have very different &#x003b3; when expressed in different membranes (<xref ref-type="bibr" rid="ref56">56</xref>). We have no definitive explanation for these disparities, but for IP<sub>3</sub>R we suggested that different membranes may selectively stabilize different sub-conductance states (<xref ref-type="bibr" rid="ref56">56</xref>). A similar explanation may account for the different &#x003b3; of RyR2 in the PM and bilayers.</p><p>We have shown that RyR2 are expressed in RINm5F cells (<xref rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>) and that their distribution is consistent with a presence in the PM (<xref rid="fig2" ref-type="fig">Fig. 2, <italic>B</italic> and <italic>C</italic></xref>). A variety of agonists of RyR (caffeine, 4CmC, ryanodine) activate both Ca<sup>2+</sup> entry in intact cells and poorly selective large-conductance cation channels in the PM. The responses are blocked by antagonists of RyR (ryanodine, ruthenium red), but not by antagonists of other cation channels. Our final experiments use RNAi to confirm that RyR2 directly mediate these responses.</p><p><italic>Inhibition of RyR2 Expression Inhibits Responses</italic>&#x02014;Using RNAi, we selectively reduced expression of RyR1, RyR2 or IP<sub>3</sub>R3 by &#x0003e;50%, without reducing expression of the non-targeted proteins (<xref rid="fig6" ref-type="fig">Fig. 6, <italic>A</italic> and <italic>B</italic></xref>, and supplemental Table S6).</p><p>In excised patch-clamp recordings from mock-transfected cells or cells transfected with RNAi to RyR1, 4CmC-activated cation channels were detected in &#x0223c;70% of recordings that achieved a G&#x003a9; seal, but the success rate fell to 21 &#x000b1; 6% for cells treated with RNAi to RyR2 (<xref rid="fig6" ref-type="fig">Fig. 6, <italic>C</italic> and <italic>D</italic></xref>). The peak Ca<sup>2+</sup> signals evoked by 4CmC, which depend largely on Ca<sup>2+</sup> entry (<xref rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>), were also selectively attenuated by treatment with RNAi to RyR2 (<xref rid="fig6" ref-type="fig">Fig. 6, <italic>F</italic> and <italic>G</italic></xref>). Likewise, the effect of 4CmC on Mn<sup>2+</sup> entry was almost abolished in cells treated with RNAi to RyR2, whereas RNAi to IP<sub>3</sub>R3 had no effect (<xref rid="fig6" ref-type="fig">Fig. 6<italic>E</italic></xref>). We conclude that RyR2 are expressed in the PM and directly mediate Ca<sup>2+</sup> entry.</p><p><italic>Expression of Functional RyR2 in the Plasma Membrane of RINm5F Cells</italic>&#x02014;We have demonstrated the expression of small numbers (&#x0223c;10 channels/cell) of functional RyR2 in the PM of RINm5F cells and provided more limited evidence for functional RyR in the PM of rat pancreatic &#x003b2;-cells. Although RyR and IP<sub>3</sub>R are widely expressed intracellular Ca<sup>2+</sup> channels, accumulating evidence suggests that the same channels may also be expressed within the PM of some cells. In B-lymphocytes, for example, very small numbers of functional IP<sub>3</sub>R (2&#x02013;3 IP<sub>3</sub>R/cell) are reliably expressed in the PM, where they mediate about half the Ca<sup>2+</sup> entry evoked by activation of the B-cell receptor (<xref ref-type="bibr" rid="ref56">56</xref>, <xref ref-type="bibr" rid="ref57">57</xref>). IP<sub>3</sub>R, possibly distinct from those in the ER, are also expressed in the PM of olfactory neurones (<xref ref-type="bibr" rid="ref58">58</xref>) and ciliated epithelia (<xref ref-type="bibr" rid="ref59">59</xref>).</p><p>Several studies have detected cation channels with large, although rather variable, conductances that are activated by agonists of RyR in the PM of different cell types. These include osteoblasts, where RyR2 are proposed to mediate extracellular Ca<sup>2+</sup>-sensing (<xref ref-type="bibr" rid="ref60">60</xref>); cardiac myocytes (<xref ref-type="bibr" rid="ref61">61</xref>) and smooth muscle (<xref ref-type="bibr" rid="ref62">62</xref>, <xref ref-type="bibr" rid="ref63">63</xref>). In each case, the density of the PM channels was very low, typically no more than &#x0223c;10 channels/cell, and often just 2&#x02013;3 channels/cell. None of these reports established the molecular identity of the channel and several were reluctant to conclude that it was a RyR (<xref ref-type="bibr" rid="ref20">20</xref>, <xref ref-type="bibr" rid="ref61">61</xref>&#x02013;<xref ref-type="bibr" rid="ref63">63</xref>), but together they provide evidence that small numbers of RyR may be expressed in the PM of several different electrically excitable cells. Our results extend these observations to RINm5F cells and pancreatic &#x003b2;-cells and, more importantly, they unequivocally establish that RyR2 expressed in the PM can directly mediate Ca<sup>2+</sup> entry.</p><p>These results indicate that in some cells, small numbers of IP<sub>3</sub>R or RyR can be expressed in the PM and mediate Ca<sup>2+</sup> entry. The small number of these channels is significant because both RyR and IP<sub>3</sub>R have such large conductances (Figs. <xref rid="fig3" ref-type="fig">3<italic>C</italic></xref>, <xref rid="fig4" ref-type="fig">4<italic>B</italic></xref>, and <xref rid="fig5" ref-type="fig">5<italic>C</italic></xref>) that very few channels can mediate substantial Ca<sup>2+</sup> entry (<xref ref-type="bibr" rid="ref56">56</xref>).</p><p>RyR are implicated in the responses of pancreatic &#x003b2;-cells to glucose and incretins (see Introduction); many diabetic states are associated with a loss of RyR from &#x003b2;-cells (<xref ref-type="bibr" rid="ref10">10</xref>); and the immunosuppressant, FK-506, which interacts with RyR via FKBP (<xref ref-type="bibr" rid="ref64">64</xref>), is a major cause of post-transplantation diabetes mellitus (<xref ref-type="bibr" rid="ref65">65</xref>). But the specific roles of RyR in &#x003b2;-cells are incompletely resolved (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref66">66</xref>). It is, however, clear that whereas both IP<sub>3</sub>R and RyR are expressed in the ER of insulinoma cells, only RyR are expressed in secretory vesicles (<xref ref-type="bibr" rid="ref8">8</xref>) or endosomes (<xref ref-type="bibr" rid="ref10">10</xref>). Selective targeting of RyR (and not IP<sub>3</sub>R) to the secretory vesicles of &#x003b2;-cells might therefore be one step that contributes to selective expression of small numbers of RyR in the PM.</p><p>Abundant evidence implicates RyR in mediating physiological responses of &#x003b2;-cells to glucose and incretins (see Introduction). Our results suggest that their involvement in these responses is likely to involve RyR within both intracellular stores and the PM, and within the latter it is likely that RyR may directly mediate Ca<sup>2+</sup> entry and contribute to regulation of membrane potential. It remains unclear whether the non-ER RyR reside predominantly in endosomes or secretory vesicles (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref10">10</xref>), but it is significant that their presence in either organelle suggests a dynamic relationship between exocytosis of insulin-containing vesicles and trafficking of RyR2 between intracellular organelles and the PM.</p><p>We have shown that small numbers of functional RyR2 are expressed in the PM of RINm5F insulinoma cells and rat pancreatic &#x003b2;-cells, where they directly mediate Ca<sup>2+</sup> entry and may also regulate membrane potential. We suggest that exocytosis of insulin-containing vesicles and the subsequent retrieval of membrane by endocytosis (<xref ref-type="bibr" rid="ref67">67</xref>) may allow dynamic regulation of RyR expression in the PM.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data"><caption><title>[Supplemental Data]</title></caption><media mimetype="text" mime-subtype="html" xlink:href="M805587200_index.html"/><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="M805587200_1.pdf"/></supplementary-material></sec></body><back><ack><p>We thank G. Meissner for providing the antiserum for RyR1, and N. Smith and S. Ozanne for help with &#x003b2;-cells.</p></ack><ref-list><ref id="ref1"><label>1</label><citation citation-type="journal">Foskett, J. K., White, C., Cheung, K. H., and Mak, D. O. (<year>2007</year>) <source>Physiol. Rev.</source><volume>87</volume><fpage>593</fpage>-658<pub-id pub-id-type="pmid">17429043</pub-id></citation></ref><ref id="ref2"><label>2</label><citation citation-type="journal">Hamilton, S. L. (<year>2005</year>) <source>Cell Calcium</source><volume>38</volume><fpage>253</fpage>-260<pub-id pub-id-type="pmid">16115682</pub-id></citation></ref><ref id="ref3"><label>3</label><citation citation-type="journal">Taylor, C. W., Genazzani, A. A., and Morris, S. A. (<year>1999</year>) <source>Cell Calcium</source><volume>26</volume><fpage>237</fpage>-251<pub-id pub-id-type="pmid">10668562</pub-id></citation></ref><ref id="ref4"><label>4</label><citation citation-type="journal">Sutko, J. L., and Airey, J. A. (<year>1996</year>) <source>Physiol. Rev.</source><volume>76</volume><fpage>1027</fpage>-1071<pub-id pub-id-type="pmid">8874493</pub-id></citation></ref><ref id="ref5"><label>5</label><citation citation-type="journal">Blondel, O., Takeda, J., Janssen, H., Seino, S., and Bell, G. I. (<year>1993</year>) <source>J. Biol. Chem.</source><volume>268</volume><fpage>11356</fpage>-11363<pub-id pub-id-type="pmid">8388391</pub-id></citation></ref><ref id="ref6"><label>6</label><citation citation-type="journal">Swatton, J. E., Morris, S. A., Cardy, T. J. A., and Taylor, C. W. (<year>1999</year>) <source>Biochem. J.</source><volume>344</volume><fpage>55</fpage>-60<pub-id pub-id-type="pmid">10548533</pub-id></citation></ref><ref id="ref7"><label>7</label><citation citation-type="journal">Islam, M. S. (<year>2002</year>) <source>Diabetes</source><volume>51</volume><fpage>1299</fpage>-1309<pub-id pub-id-type="pmid">11978625</pub-id></citation></ref><ref id="ref8"><label>8</label><citation citation-type="journal">Mitchell, K. J., Pinton, P., Varadi, A., Tacchetti, C., Ainscow, E. K., Pozzan, T., Rizzuto, R., and Rutter, G. A. (<year>2001</year>) <source>J. Cell Biol.</source><volume>155</volume><fpage>41</fpage>-51<pub-id pub-id-type="pmid">11571310</pub-id></citation></ref><ref id="ref9"><label>9</label><citation citation-type="journal">Mitchell, K. J., Lai, F. A., and Rutter, G. A. (<year>2003</year>) <source>J. Biol. Chem.</source><volume>278</volume><fpage>11057</fpage>-11064<pub-id pub-id-type="pmid">12538591</pub-id></citation></ref><ref id="ref10"><label>10</label><citation citation-type="journal">Johnson, J. D., Kuang, S., Misler, S., and Polonsky, K. S. (<year>2004</year>) <source>FASEB J.</source><volume>18</volume><fpage>878</fpage>-880<pub-id pub-id-type="pmid">15033925</pub-id></citation></ref><ref id="ref11"><label>11</label><citation citation-type="journal">Blondel, O., Bell, G. I., Moody, M., Miller, R. J., and Gibbons, S. J. (<year>1994</year>) <source>J. Biol. Chem.</source><volume>269</volume><fpage>27167</fpage>-27170<pub-id pub-id-type="pmid">7961623</pub-id></citation></ref><ref id="ref12"><label>12</label><citation citation-type="journal">Ravazzola, M., Halban, P. A., and Orci, L. (<year>1996</year>) <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>93</volume><fpage>2745</fpage>-2748<pub-id pub-id-type="pmid">8610112</pub-id></citation></ref><ref id="ref13"><label>13</label><citation citation-type="journal">Prentki, M., Biden, T. J., Janjic, D., Irvine, R. F., Berridge, M. J., and Wollheim, C. B. (<year>1984</year>) <source>Nature</source><volume>309</volume><fpage>562</fpage>-564<pub-id pub-id-type="pmid">6328320</pub-id></citation></ref><ref id="ref14"><label>14</label><citation citation-type="journal">Takasawa, S., Akiyama, T., Nata, K., Kuroki, M., Tohgo, A., Noguchi, N., Kobayashi, S., Kato, I., Katada, T., and Okamoto, H. (<year>1998</year>) <source>J. Biol. Chem.</source><volume>273</volume><fpage>2497</fpage>-2500<pub-id pub-id-type="pmid">9446548</pub-id></citation></ref><ref id="ref15"><label>15</label><citation citation-type="journal">Patterson, R. L., Boehning, D., and Snyder, S. H. (<year>2004</year>) <source>Annu. Rev. Biochem.</source><volume>73</volume><fpage>437</fpage>-465<pub-id pub-id-type="pmid">15189149</pub-id></citation></ref><ref id="ref16"><label>16</label><citation citation-type="journal">Bers, D. M. (<year>2004</year>) <source>J. Mol. Cell. Cardiol.</source><volume>37</volume><fpage>417</fpage>-429<pub-id pub-id-type="pmid">15276012</pub-id></citation></ref><ref id="ref17"><label>17</label><citation citation-type="journal">Williams, A. J. (<year>2002</year>) <source>Front. Biosci.</source><volume>7</volume><fpage>1</fpage>-8</citation></ref><ref id="ref18"><label>18</label><citation citation-type="journal">Gillespie, D., and Fill, M. (<year>2008</year>) <source>Biophys. J.</source><volume>95</volume><fpage>3706</fpage>-3714<pub-id pub-id-type="pmid">18621826</pub-id></citation></ref><ref id="ref19"><label>19</label><citation citation-type="journal">Nichols, C. G. (<year>2006</year>) <source>Nature</source><volume>440</volume><fpage>470</fpage>-476<pub-id pub-id-type="pmid">16554807</pub-id></citation></ref><ref id="ref20"><label>20</label><citation citation-type="journal">Gustafsson, A. J., Ingelman-Sundberg, H., Dzabic, M., Awasum, J., Nguyen, K. H., Ostenson, C. G., Pierro, C., Tedeschi, P., Woolcott, O., Chiounan, S., Lund, P. E., Larsson, O., and Islam, M. S. (<year>2005</year>) <source>FASEB J.</source><volume>19</volume><fpage>301</fpage>-303<pub-id pub-id-type="pmid">15572434</pub-id></citation></ref><ref id="ref21"><label>21</label><citation citation-type="journal">Ashcroft, F. M., Proks, P., Smith, P. A., Ammala, C., Bokvist, K., and Rorsman, P. (<year>1994</year>) <source>J. Cell. Biochem.</source><volume>55</volume> (suppl.), <fpage>54</fpage>-65<pub-id pub-id-type="pmid">7929618</pub-id></citation></ref><ref id="ref22"><label>22</label><citation citation-type="journal">Bokvist, K., Eliasson, L., Ammala, C., Renstrom, E., and Rorsman, P. (<year>1995</year>) <source>EMBO J.</source><volume>14</volume><fpage>50</fpage>-57<pub-id pub-id-type="pmid">7828595</pub-id></citation></ref><ref id="ref23"><label>23</label><citation citation-type="journal">Wiederkehr, A., and Wollheim, C. B. (<year>2006</year>) <source>Endocrinology</source><volume>147</volume><fpage>2643</fpage>-2649<pub-id pub-id-type="pmid">16556766</pub-id></citation></ref><ref id="ref24"><label>24</label><citation citation-type="journal">Rojas, E., Carroll, P. B., Ricordi, C., Boschero, A. C., Stojilkovic, S. S., and Atwater, I. (<year>1994</year>) <source>Endocrinology</source><volume>134</volume><fpage>1771</fpage>-1781<pub-id pub-id-type="pmid">8137742</pub-id></citation></ref><ref id="ref25"><label>25</label><citation citation-type="journal">Henquin, J. C. (<year>2000</year>) <source>Diabetes</source><volume>49</volume><fpage>1751</fpage>-1760<pub-id pub-id-type="pmid">11078440</pub-id></citation></ref><ref id="ref26"><label>26</label><citation citation-type="journal">Shigeto, M., Katsura, M., Matsuda, M., Ohkuma, S., and Kaku, K. (<year>2007</year>) <source>J. Pharmacol. Exp. Ther.</source><volume>322</volume><fpage>1</fpage>-7<pub-id pub-id-type="pmid">17409272</pub-id></citation></ref><ref id="ref27"><label>27</label><citation citation-type="journal">Dyachok, O., and Gylfe, E. (<year>2004</year>) <source>J. Biol. Chem.</source><volume>279</volume><fpage>45455</fpage>-45461<pub-id pub-id-type="pmid">15316011</pub-id></citation></ref><ref id="ref28"><label>28</label><citation citation-type="journal">Kermode, H., Williams, A. J., and Sitsapesan, R. (<year>1998</year>) <source>Biophys. J.</source><volume>74</volume><fpage>1296</fpage>-1304<pub-id pub-id-type="pmid">9512027</pub-id></citation></ref><ref id="ref29"><label>29</label><citation citation-type="journal">Drucker, D. J. (<year>2006</year>) <source>Cell Metab.</source><volume>3</volume><fpage>153</fpage>-165<pub-id pub-id-type="pmid">16517403</pub-id></citation></ref><ref id="ref30"><label>30</label><citation citation-type="journal">Holst, J. J. (<year>2007</year>) <source>Physiol. Rev.</source><volume>87</volume><fpage>1409</fpage>-1439<pub-id pub-id-type="pmid">17928588</pub-id></citation></ref><ref id="ref31"><label>31</label><citation citation-type="journal">Holz, G. G. (<year>2004</year>) <source>Diabetes</source><volume>53</volume><fpage>5</fpage>-13<pub-id pub-id-type="pmid">14693691</pub-id></citation></ref><ref id="ref32"><label>32</label><citation citation-type="journal">Szaszak, M., Christian, F., Rosenthal, W., and Klussmann, E. (<year>2007</year>) <source>Cell. Signal.</source><volume>20</volume><fpage>590</fpage>-601<pub-id pub-id-type="pmid">18061403</pub-id></citation></ref><ref id="ref33"><label>33</label><citation citation-type="journal">Holz, G. G., Leech, C. A., Heller, R. S., Castonguay, M., and Habener, J. F. (<year>1999</year>) <source>J. Biol. Chem.</source><volume>274</volume><fpage>14147</fpage>-14156<pub-id pub-id-type="pmid">10318832</pub-id></citation></ref><ref id="N0x3b58ca0N0x428f580"><label>34</label><citation citation-type="journal">Tsuboi, T., da Silva Xavier, G., Holz, G. G., Jouaville, L. S., Thomas, A. P., and Rutter, G. A. (<year>2003</year>) <source>Biochem. J.</source><volume>369</volume><fpage>287</fpage>-299<pub-id pub-id-type="pmid">12410638</pub-id></citation></ref><ref id="ref35"><label>35</label><citation citation-type="journal">Kang, G., Chepurny, O. G., and Holz, G. G. (<year>2001</year>) <source>J. Physiol.</source><volume>536</volume><fpage>375</fpage>-385<pub-id pub-id-type="pmid">11600673</pub-id></citation></ref><ref id="ref36"><label>36</label><citation citation-type="journal">Gromada, J., Dissing, S., Bokvist, K., Renstr&#x000f6;m, E., Fr&#x000f8;kjaer-Jensen, J., Wulff, B. S., and Rorsman, P. (<year>1995</year>) <source>Diabetes</source><volume>44</volume><fpage>767</fpage>-774<pub-id pub-id-type="pmid">7789644</pub-id></citation></ref><ref id="ref37"><label>37</label><citation citation-type="journal">Dyachok, O., Isakov, Y., Sagetorp, J., and Tengholm, A. (<year>2006</year>) <source>Nature</source><volume>439</volume><fpage>349</fpage>-352<pub-id pub-id-type="pmid">16421574</pub-id></citation></ref><ref id="ref38"><label>38</label><citation citation-type="journal">Lacy, P. E., and Kostianovsky, M. (<year>1967</year>) <source>Diabetes</source><volume>16</volume><fpage>35</fpage>-39<pub-id pub-id-type="pmid">5333500</pub-id></citation></ref><ref id="ref39"><label>39</label><citation citation-type="journal">Meissner, G., Rousseau, E., and Lai, F. A. (<year>1989</year>) <source>J. Biol. Chem.</source><volume>264</volume><fpage>1715</fpage>-1722<pub-id pub-id-type="pmid">2536370</pub-id></citation></ref><ref id="ref40"><label>40</label><citation citation-type="journal">Warton, K., Foster, N. C., Gold, W. A., and Stanley, K. K. (<year>2004</year>) <source>Gene</source><volume>342</volume><fpage>85</fpage>-95<pub-id pub-id-type="pmid">15527968</pub-id></citation></ref><ref id="ref41"><label>41</label><citation citation-type="journal">Fessenden, J. D., Perez, C. F., Goth, S., Pessah, I. N., and Allen, P. D. (<year>2003</year>) <source>J. Biol. Chem.</source><volume>278</volume><fpage>28727</fpage>-28735<pub-id pub-id-type="pmid">12761215</pub-id></citation></ref><ref id="ref42"><label>42</label><citation citation-type="journal">Woolcott, O. O., Gustafsson, A. J., Dzabic, M., Pierro, C., Tedeschi, P., Sandgren, J., Bari, M. R., Nguyen, K. H., Bianchi, M., Rakonjac, M., Radmark, O., Ostenson, C. G., and Islam, M. S. (<year>2006</year>) <source>Cell Calcium</source><volume>39</volume><fpage>529</fpage>-537<pub-id pub-id-type="pmid">16620964</pub-id></citation></ref><ref id="ref43"><label>43</label><citation citation-type="journal">Parekh, A. B., and Putney, J. W. (<year>2005</year>) <source>Physiol. Rev.</source><volume>85</volume><fpage>757</fpage>-810<pub-id pub-id-type="pmid">15788710</pub-id></citation></ref><ref id="ref44"><label>44</label><citation citation-type="journal">Yamasaki, M., Masgrau, R., Morgan, A. J., Churchill, G. C., Patel, S., Ashcroft, S. J., and Galione, A. (<year>2004</year>) <source>J. Biol. Chem.</source><volume>279</volume><fpage>7234</fpage>-7240<pub-id pub-id-type="pmid">14660554</pub-id></citation></ref><ref id="ref45"><label>45</label><citation citation-type="journal">Liu, Y. J., and Gylfe, E. (<year>1997</year>) <source>Cell Calcium</source><volume>22</volume><fpage>277</fpage>-286<pub-id pub-id-type="pmid">9481478</pub-id></citation></ref><ref id="N0x3b58ca0N0x1dd5c88"><label>46</label><citation citation-type="journal">Miura, Y., Henquin, J. C., and Gilon, P. (<year>1997</year>) <source>J. Physiol.</source><volume>503</volume><fpage>387</fpage>-398<pub-id pub-id-type="pmid">9306280</pub-id></citation></ref><ref id="ref47"><label>47</label><citation citation-type="journal">Mears, D., Leighton, X., Atwater, I., and Rojas, E. (<year>1999</year>) <source>Cell Calcium</source><volume>25</volume><fpage>59</fpage>-68<pub-id pub-id-type="pmid">10191960</pub-id></citation></ref><ref id="ref48"><label>48</label><citation citation-type="journal">Lee, B., Bradford, P. G., and Laychock, S. G. (<year>1998</year>) <source>J. Mol. Endocrinol.</source><volume>21</volume><fpage>31</fpage>-39<pub-id pub-id-type="pmid">9723861</pub-id></citation></ref><ref id="ref49"><label>49</label><citation citation-type="journal">Johnson, J. D., Han, Z., Otani, K., Ye, H., Zhang, Y., Wu, H., Horikawa, Y., Misler, S., Bell, G. I., and Polonsky, K. S. (<year>2004</year>) <source>J. Biol. Chem.</source><volume>279</volume><fpage>24794</fpage>-24802<pub-id pub-id-type="pmid">15044459</pub-id></citation></ref><ref id="ref50"><label>50</label><citation citation-type="journal">Santonastasi, M., and Wehrens, X. H. (<year>2007</year>) <source>Acta Pharma. Sin.</source><volume>28</volume><fpage>937</fpage>-944</citation></ref><ref id="ref51"><label>51</label><citation citation-type="journal">Tian, M., Dong, M. Q., Chiu, S. W., Lau, C. P., and Li, G. R. (<year>2006</year>) <source>Br. J. Pharmacol.</source><volume>147</volume><fpage>289</fpage>-297<pub-id pub-id-type="pmid">16341233</pub-id></citation></ref><ref id="ref52"><label>52</label><citation citation-type="journal">Welker, S., and Drews, G. (<year>1997</year>) <source>Naunyn-Shmiedeberg's Arch. Pharmacol.</source><volume>356</volume><fpage>543</fpage>-550</citation></ref><ref id="ref53"><label>53</label><citation citation-type="journal">Fill, M., and Copello, J. A. (<year>2002</year>) <source>Physiol. Rev.</source><volume>82</volume><fpage>893</fpage>-922<pub-id pub-id-type="pmid">12270947</pub-id></citation></ref><ref id="ref54"><label>54</label><citation citation-type="journal">Lindsay, A. R. G., Manning, S. D., and Williams, A. J. (<year>1991</year>) <source>J. Physiol.</source><volume>439</volume><fpage>463</fpage>-480<pub-id pub-id-type="pmid">1716676</pub-id></citation></ref><ref id="ref55"><label>55</label><citation citation-type="journal">Williams, A. J., West, D. J., and Sitsapesan, R. (<year>2001</year>) <source>Quart. Rev. Biophys.</source><volume>34</volume><fpage>61</fpage>-104</citation></ref><ref id="ref56"><label>56</label><citation citation-type="journal">Dellis, O., Dedos, S., Tovey, S. C., Rahman, T.-U., Dubel, S. J., and Taylor, C. W. (<year>2006</year>) <source>Science</source><volume>313</volume><fpage>229</fpage>-233<pub-id pub-id-type="pmid">16840702</pub-id></citation></ref><ref id="ref57"><label>57</label><citation citation-type="journal">Dellis, O., Rossi, A. M., Dedos, S. G., and Taylor, C. W. (<year>2008</year>) <source>J. Biol. Chem.</source><volume>283</volume><fpage>751</fpage>-755<pub-id pub-id-type="pmid">17999955</pub-id></citation></ref><ref id="ref58"><label>58</label><citation citation-type="journal">Fadool, D. A., and Ache, B. W. (<year>1992</year>) <source>Neuron</source><volume>9</volume><fpage>907</fpage>-918<pub-id pub-id-type="pmid">1384577</pub-id></citation></ref><ref id="ref59"><label>59</label><citation citation-type="journal">Barrera, N. P., Morales, B., and Villalon, M. (<year>2007</year>) <source>Biochem. Biophys. Res. Commun.</source><volume>364</volume><fpage>815</fpage>-821<pub-id pub-id-type="pmid">18163243</pub-id></citation></ref><ref id="ref60"><label>60</label><citation citation-type="journal">Huang, C. L., Sun, L., Fraser, J. A., Grace, A. A., and Zaidi, M. (<year>2007</year>) <source>Ann. N. Y. Acad. Sci.</source><volume>1116</volume><fpage>255</fpage>-270<pub-id pub-id-type="pmid">18083933</pub-id></citation></ref><ref id="ref61"><label>61</label><citation citation-type="journal">Zhang, Y. A., Tuft, R. A., Lifshitz, L. M., Fogarty, K. E., Singer, J. J., and Zou, H. (<year>2007</year>) <source>Am. J. Physiol.</source><volume>293</volume><fpage>H2448</fpage>-H2461</citation></ref><ref id="ref62"><label>62</label><citation citation-type="journal">Guerrero, A., Fay, F. S., and Singer, J. J. (<year>1994</year>) <source>J. Gen. Physiol.</source><volume>104</volume><fpage>375</fpage>-394<pub-id pub-id-type="pmid">7807054</pub-id></citation></ref><ref id="ref63"><label>63</label><citation citation-type="journal">Loirand, G., Pacaud, P., Baron, A., Mironneau, C., and Mironneau, J. (<year>1991</year>) <source>J. Physiol.</source><volume>437</volume><fpage>461</fpage>-475<pub-id pub-id-type="pmid">1716314</pub-id></citation></ref><ref id="ref64"><label>64</label><citation citation-type="journal">Samso, M., Shen, X., and Allen, P. D. (<year>2006</year>) <source>J. Mol. Biol.</source><volume>356</volume><fpage>917</fpage>-927<pub-id pub-id-type="pmid">16405911</pub-id></citation></ref><ref id="ref65"><label>65</label><citation citation-type="journal">Penfornis, A., and Kury-Paulin, S. (<year>2006</year>) <source>Diabetes Metab.</source><volume>32</volume><fpage>539</fpage>-546<pub-id pub-id-type="pmid">17130815</pub-id></citation></ref><ref id="ref66"><label>66</label><citation citation-type="journal">Zhan, X., Yang, L., Yi, M., and Jia, Y. (<year>2008</year>) <source>Eur. J. Biophys.</source><volume>37</volume><fpage>773</fpage>-782</citation></ref><ref id="ref67"><label>67</label><citation citation-type="journal">MacDonald, P. E., and Rorsman, P. (<year>2007</year>) <source>Physiology (Bethesda)</source><volume>22</volume><fpage>113</fpage>-121<pub-id pub-id-type="pmid">17420302</pub-id></citation></ref></ref-list><fn-group><fn id="fn5"><label>3</label><p>The abbreviations used are: RyR, ryanodine receptor; BS, bath solution; [Ca<sup>2+</sup>]<italic><sub>i</sub></italic>, free intracellular Ca<sup>2+</sup> concentration; 4CmC, 4-chloro-<italic>m</italic>-cresol; ER, endoplasmic reticulum; &#x003b3;, single channel slope conductance; HBS, Hepes-buffered saline; IP<sub>3</sub>R, inositol 1,4,5-trisphosphate receptor; PBS, phosphate-buffered saline; PM, plasma membrane; <italic>P</italic><sub>o</sub>, single channel open probability; PS, pipette solution.</p></fn></fn-group></back></article> 